Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2001
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.
Epistemonikos ID: d742798b535254ee61029893095643fec3027437
First added on: May 04, 2024